Por favor, use este identificador para citar o enlazar este ítem:
https://www.arca.fiocruz.br/handle/icict/30162
Tipo
ArtículoDerechos de autor
Acceso abierto
Colecciones
- INI - Artigos de Periódicos [3397]
Metadatos
Mostrar el registro completo del ítem
LONG-TERM EFFICACY AND SAFETY OF RALTEGRAVIR COMBINED WITH OPTIMIZED BACKGROUND THERAPY IN TREATMENT-EXPERIENCED PATIENTS WITH DRUG-RESISTANT HIV INFECTION: WEEK 96 RESULTS OF THE BENCHMRK 1 AND 2 PHASE III TRIALS
CD4 Lymphocyte Count
Drug Therapy
Drug Resistance
Pyrrolidinones
Raltegravir Potassium
HIV-1
Autor
Steigbigel, Roy T.
Cooper, David A.
Teppler, Hedy
Eron, Joseph J.
Gatell, Jose M.
Kumar, Princy N.
Rockstroh, Jurgen K.
Schechter, Mauro
Katlama, Christine
Markowitz, Martin
Yeni, Patrick
Loutfy, Mona R.
Lazzarin, Adriano
Lennox, Jeffrey L.
Clotet, Bonaventura
Zhao, Jing
Wan, Hong
Rhodes, Rand R.
Strohmaier, Kim M.
Barnard, Richard J.
Isaacs, Robin D.
Nguyen, Bach-Yen T.
BENCHMRK Study Team
Cooper, David A.
Teppler, Hedy
Eron, Joseph J.
Gatell, Jose M.
Kumar, Princy N.
Rockstroh, Jurgen K.
Schechter, Mauro
Katlama, Christine
Markowitz, Martin
Yeni, Patrick
Loutfy, Mona R.
Lazzarin, Adriano
Lennox, Jeffrey L.
Clotet, Bonaventura
Zhao, Jing
Wan, Hong
Rhodes, Rand R.
Strohmaier, Kim M.
Barnard, Richard J.
Isaacs, Robin D.
Nguyen, Bach-Yen T.
BENCHMRK Study Team
Afiliación
State University of New York. Stony Brook, USA.
University of New South Wales. National Centre in HIV Epidemiology and Clinical Research. Sydney, Australia.
Merck Research Laboratories. North Wales, Pennsylvania, USA.
University of North Carolina. Chapel Hill, USA.
Universidad de Barcelona. Hospital Clinic-IDIBAPS. Barcelona, España.
Georgetown University Medical Center. Washington, DC, USA.
University of Bonn. Department of Medicine I. Bonn, Germany.
Universidade Federal do Rio de Janeiro. Rio de Janeiro, Brasil.
Université Pierre et Marie Curie. Hospital Pitié Salpêtrière. Paris, France.
The Rockefeller University. Aaron Diamond Research Center. New York, NY, USA.
Hospital Bichat-Claude Bernard. Paris, France.
University of Toronto. Toronto, ON, Canada.
San Raffaele Scientific Institute. Milan, Italy.
Emory University School of Medicine. Atlanta, GA, USA.
Universitat Autònoma de Barcelona. Fundación Irsicaixa. Hospital Germans Trias i Pujol. Barcelona, España.
Merck Research Laboratories. North Wales, PA, USA.
Merck Research Laboratories. North Wales, PA, USA.
Merck Research Laboratories. North Wales, PA, USA.
Merck Research Laboratories. North Wales, PA, USA.
Merck Research Laboratories. North Wales, PA, USA.
Merck Research Laboratories. North Wales, PA, USA.
Merck Research Laboratories. North Wales, PA, USA.
University of New South Wales. National Centre in HIV Epidemiology and Clinical Research. Sydney, Australia.
Merck Research Laboratories. North Wales, Pennsylvania, USA.
University of North Carolina. Chapel Hill, USA.
Universidad de Barcelona. Hospital Clinic-IDIBAPS. Barcelona, España.
Georgetown University Medical Center. Washington, DC, USA.
University of Bonn. Department of Medicine I. Bonn, Germany.
Universidade Federal do Rio de Janeiro. Rio de Janeiro, Brasil.
Université Pierre et Marie Curie. Hospital Pitié Salpêtrière. Paris, France.
The Rockefeller University. Aaron Diamond Research Center. New York, NY, USA.
Hospital Bichat-Claude Bernard. Paris, France.
University of Toronto. Toronto, ON, Canada.
San Raffaele Scientific Institute. Milan, Italy.
Emory University School of Medicine. Atlanta, GA, USA.
Universitat Autònoma de Barcelona. Fundación Irsicaixa. Hospital Germans Trias i Pujol. Barcelona, España.
Merck Research Laboratories. North Wales, PA, USA.
Merck Research Laboratories. North Wales, PA, USA.
Merck Research Laboratories. North Wales, PA, USA.
Merck Research Laboratories. North Wales, PA, USA.
Merck Research Laboratories. North Wales, PA, USA.
Merck Research Laboratories. North Wales, PA, USA.
Merck Research Laboratories. North Wales, PA, USA.
Resumen en ingles
BENCHMRK-1 and -2 are ongoing double-blind phase III studies of raltegravir in patients experiencing failure of antiretroviral therapy with triple-class drug-resistant human immunodeficiency virus infection. At week 96 (combined data), raltegravir (400 mg twice daily) plus optimized background therapy was generally well tolerated, with superior and durable antiretroviral and immunological efficacy, compared with optimized background therapy alone.
Palabras clave en ingles
Anti-HIV AgentsCD4 Lymphocyte Count
Drug Therapy
Drug Resistance
Pyrrolidinones
Raltegravir Potassium
HIV-1
Compartir